{"id":"glucagon-hydrochloride-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL5314342","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucagon is a peptide hormone that activates G-protein coupled glucagon receptors, primarily on hepatocytes. This triggers intracellular signaling cascades that promote the breakdown of stored glycogen to glucose and the synthesis of new glucose from precursors, effectively counteracting hypoglycemia. The hydrochloride salt formulation allows for parenteral administration in acute hypoglycemic emergencies.","oneSentence":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:01.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypoglycemia in patients with diabetes mellitus"},{"name":"Diagnostic aid in radiologic examination of the gastrointestinal tract"}]},"trialDetails":[{"nctId":"NCT02205528","phase":"PHASE2","title":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-18","conditions":"Diabetes, Diabetes Mellitus Type 2","enrollment":108},{"nctId":"NCT03533179","phase":"PHASE4","title":"Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2018-06-01","conditions":"Drug Overdose, Overdose of Beta-adrenergic Blocking Drug","enrollment":10},{"nctId":"NCT03421379","phase":"PHASE3","title":"A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-21","conditions":"Diabetes Mellitus","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GlucaGen®"],"phase":"phase_3","status":"active","brandName":"Glucagon Hydrochloride Solution","genericName":"Glucagon Hydrochloride Solution","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Severe hypoglycemia in patients with diabetes mellitus, Diagnostic aid in radiologic examination of the gastrointestinal tract.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1998-06-22T00:00:00.000Z","mah":"NOVO NORDISK","brand_name_local":"GLUCAGEN","application_number":"NDA020918"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}